TO THE EDITOR:
In their superb review on antibiotic resistance in the intensive care unit (1), Drs. Kollef and Fraser incorrectly defined our approach to nosocomial pulmonary infiltrates. We did not quantitate the risk for nosocomial pneumonia but used a scoring system merely as an operational criterion for decision making about antibiotic therapy, regardless of whether patients had nosocomial pneumonia (2) . Patients who had low clinical pulmonary infection scores (and were unlikely to have bacterial pneumonia) were randomly assigned to standard therapy, usually defined as multiple antibiotics for 10 or more days, or monotherapy for 3 days. Our approach, regardless of the precise definition or presence of nosocomial pneumonia, was associated with a significantly lower risk for antimicrobial resistance and superinfections and did not adversely affect length of stay or mortality.
Drs. Kollef and Fraser proposed many administrative approaches to curtail antibiotic resistance in the intensive care unit. Such strategies have largely been ineffective in altering prescribing habits of physicians. During our study, after realizing that their standard antibiotic practices were causing measurable harm to their patients, physicians voluntarily decreased antibiotic usage in the intensive care unit. This type of strategy is more likely to lead to enduring changes in antibiotic prescribing than imposed regulations. In addition, studies attempting to define the impact of antibiotic resistance on clinical outcomes need to take severity of illness and other underlying patient characteristics into account. Only in this way can accurate estimates be made concerning the impact of antibiotic resistance on hospital mortality and other clinical outcomes. We also thank Drs. Singh and Yu for clarifying how they used the clinical pulmonary infection score in their clinical trial. More studies that define optimal management practices for the use of antibiotics among hospitalized patients are needed. These studies must define the costs and benefits of antibiotic exposure, as well as the potential harm caused by increasing the burden of antibiotic-resistant microorganisms in the hospital setting.
Viral Pneumonia as a Serious Complication of Etanercept Therapy
TO THE EDITOR: Levels of tumor necrosis factor are elevated in the synovial fluid of patients with rheumatoid arthritis. Etanercept inhibits tumor necrosis factor and is an effective treatment for rheumatoid arthritis (1, 2) . Tumor necrosis factor is also integral to the immune response to many pathogens, including respiratory viruses (3). We report a case of severe parainfluenza pneumonia in a patient taking etanercept.
A 54-year-old woman with severe rheumatoid arthritis presented with 10 days of dyspnea, pharyngitis, and headache. Examination revealed mild respiratory distress, fever (body temperature, 83°C), and evidence of chronic rheumatoid arthritis and long-term steroid use. She had diffuse rales and a moderate holosystolic murmur (she had known aortic insufficiency). The leukocyte count was 5.1 ϫ 10 9 cells/L, and studies of arterial blood revealed a pH of 7.45, PCO 2 of 35 mm Hg, and PO 2 of 68 mm Hg. Chest radiography showed a diffuse reticulonodular pulmonary pattern. The patient was hospitalized, and erythromycin and ceftriaxone were empirically administered.
Bacterial cultures of blood and sputum were nondiagnostic. Respiratory status worsened, requiring mechanical ventilation. A direct fluorescent antibody assay (Bartels Viral Respiratory Screening and Identification Kit, Medvet Diagnostics, Thebarton, South Australia, Australia) revealed parainfluenza virus type 3. Although ribavirin was not administered, the patient's condition improved and she was discharged on day 21.
Tumor necrosis factor may be particularly important in the immune response to some respiratory viruses (3). By inhibiting tumor necrosis factor, etanercept may allow benign respiratory viral infections to progress. In fact, clinical etanercept trials demonstrate a trend of increased respiratory infections in the treatment groups (1, 2, 4, 5) (Table) . However, these studies may not have been sufficiently powered to demonstrate a difference in this outcome because of their relatively small sample sizes. We conclude that patients being treated with etanercept may benefit from close monitoring for symptoms of upper respiratory tract infections and that discontinuation of therapy may be indicated during viral respiratory syndromes. Further study of the relationship between etanercept therapy and respiratory viral infections may be warranted. 
Abuse of Epinephrine as a Stimulant
TO THE EDITOR: New forms of drug abuse are regularly reported, but the use of catecholamines appears to be unusual (1). We report an attempt to obtain stimulant effects through intravenous epinephrine injection.
A 33-year-old man was discovered by a nurse in the bathroom of a small hospital. He was lying on the floor with an empty syringe nearby. He was conscious, with tremors and a Glasgow coma score of 14. His heart rate was 150 beats/min on the electrocardiographic monitor, but no pulse was detected. Twenty minutes later, on physician arrival, the patient was conscious, with an arterial blood pressure of 80/45 mm Hg, a heart rate of 70 beats/min, and a respiratory rate of 12 breaths/min. Findings on clinical examination and results of electrocardiography were normal. The patient explained that he had achieved a satisfactory psychostimulant effect the previous day by experimenting with an intravenous injection of 0.5 mg of epinephrine in association with oxazepam ingestion. On this second attempt, he had injected 1 mg of epinephrine. He had planned to inject dobutamine as well but could not because of tremors. He was Letters admitted to the emergency department for observation, and his course was uneventful, resulting in discharge a few hours later. Stimulant abuse is common, but catecholamine use to obtain a stimulant effect is infrequent (1-3) . To our knowledge, in previous reported cases, epinephrine overdose has uniformly been accidental or iatrogenic (1, 2) . These overdoses have been associated with tachycardia, premature ventricular contractions, and myocardial ischemia (2) . In our case, we speculate that the pulseless electrical activity probably represented ventricular tachycardia, which spontaneously converted to sinus rhythm. The short half-life of epinephrine may have been responsible for this favorable outcome. Physicians should be aware of the potential for adverse cardiovascular effects following voluntary intravenous injection with epinephrine. 
